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Abstract—Type III hyperlipoproteinemia (HLP) is mainly found in homozygous carriers of apolipoprotein E2 (apoE2,
Arg1583Cys). Only a small percentage (5%) of these apoE2 homozygotes develops hyperlipidemia, indicating that
additional environmental and genetic factors contribute to the expression of type III HLP. In the present study, first, the
prevalence of type III HLP among apoE2 homozygotes was estimated in a Dutch population sample of 8888
participants. Second, 68 normocholesterolemic and 162 hypercholesterolemic apoE2 homozygotes (type III HLP
patients) were collected to investigate additional factors influencing type III HLP expression. In the Dutch population
sample, apoE2 homozygosity occurred with a frequency of 0.6% (57 of 8888 individuals). Among the 57 E2/2 subjects,
10 type III HLP patients were identified (prevalence 18%). Comparison of normocholesterolemic E2/2 subjects and type
III HLP patients showed that the latter had a significantly increased body mass index (25.64.0 versus 26.93.8 kg/m2,
respectively; P0.03) and prevalence of hyperinsulinemia (26% versus 63%, respectively; P0.001). Multiple linear
regression analysis demonstrated that most of the variability in type III HLP expression can be explained by fasting
insulin levels (partial correlation coefficient 0.50, P0.001). In contrast to men, apoE2 homozygous women aged
50 years had significantly higher plasma lipid levels than their counterparts aged 50 years. These data demonstrate
that the expression of type III HLP in E2/2 subjects is elicited to a large extent by hyperinsulinemia. In addition, in
female apoE2 homozygotes, the expression increases with age; this increase is most likely due to the loss of estrogen
production. (Arterioscler Thromb Vasc Biol. 2002;22:294-299.)
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Familial dysbetalipoproteinemia (FD) is an inborn error ofmetabolism characterized by defective apoE, leading to
the impaired clearance of remnant lipoproteins by the liver.1,2
FD subjects are characterized by an accumulation of chylo-
micron and VLDL remnants in the circulation. These so-
called -VLDL particles are enriched in cholesterol esters
and apoE.3,4
ApoE is a ligand for the receptor-mediated uptake of
chylomicron and VLDL remnants by the liver.5–7 Three
alleles encode for 3 apoE isoforms: apoE2 (Arg1583Cys),
apoE3 (Cys112, Arg158), and apoE4 (Cys1123Arg).8 In
contrast to the other 2 common apoE isoforms, apoE2
displays 1% binding affinity for the hepatic LDL receptor
(LDLR).9,10 More than 90% of all FD subjects are homozy-
gous carriers of apoE2 (Arg1583Cys).1,11 In white popula-
tions, apoE2 homozygosity occurs with a frequency of1%.2
Despite the accumulation of remnants in the circulation,
most (95%) apoE2 homozygous subjects are normolipi-
demic or even hypolipidemic because of low LDL cholesterol
levels.11–13 However, apoE2 homozygosity together with the
presence of additional environmental and/or genetic factors
that interfere with normal lipoprotein metabolism will often
result in a hyperlipidemic phenotype known as type III
hyperlipoproteinemia (HLP).13
It has been suggested that the expression of type III HLP is
influenced by factors that stimulate the production of lipopro-
teins (eg, obesity, diabetes mellitus, and excessive caloric
intake), by impaired clearance (eg, decreased LDLR activity
secondary to increasing age, hypothyroidism, or low estrogen
levels during menopause), or by impaired lipolysis.2,3,14–17
Hyperinsulinemia is known to stimulate VLDL production
(see review18). Resistance to insulin-stimulated glucose up-
take results in compensatory hyperinsulinemia and, subse-
quently, a decreased uptake and/or an increased release of
free fatty acids (FFAs) by adipose tissue. An increased FFA
flux stimulates the secretion of VLDL in humans (see
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review19). In a previous study, we analyzed a group of 49
apoE2 homozygotes, including normolipidemic E2/2 subjects
and type III HLP patients. An association of high insulin
levels with type III HLP expression was observed, whereas an
interaction between hyperinsulinemia and the SstI poly-
morphism in apoC3 resulted in severe hyperlipidemia.20
The low frequency of overt type III HLP (1 to 5 per 5000
in white populations13,21) makes it difficult to collect a sample
large enough to identify the additional factors necessary for
the expression of the disorder. Furthermore, most reported
studies included only type III HLP patients, whereas no
comparison with normolipidemic E2/2 subjects was made. In
the present study, a multicenter study was used to include
normocholesterolemic and hypercholesterolemic E2/2 sub-
jects. This approach enabled us to determine any additional
factors contributing to the expression of type III HLP in a
population of 230 apoE2 homozygotes. In addition, we have
estimated the prevalence of type III HLP among apoE2
homozygotes in a Dutch population sample.
Methods
The Methods section can be found online at http://www.atvb.
ahajournals.org.
Results
Prevalence of Type III HLP Among E2/2 Subjects
in the Dutch Population Sample
Data from the Rotterdam Study (n6870) and the Dutch
population study among 2018 randomly selected 35-year-old
men were combined to determine the prevalence of apoE2
homozygosity in the Netherlands.
Of 8888 participants, 57 (0.6%) were homozygous carriers
of apoE2 (Arg1583Cys). Among the 57 E2/2 subjects, 10
type III HLP patients (7 in the Rotterdam Study and 3 in the
population study among 35-year-old men) were identified.
Thus, the prevalence of type III HLP among E2/2 subjects in
the Dutch population sample was 18%.
Influence of Additional Factors on the Expression
of Type III HLP
Characteristics of Normocholesterolemic E2/2 Subjects
and Type III HLP Patients
To determine additional factors that contribute to the expres-
sion of type III HLP in apoE2 homozygotes, clinical and
biochemical characteristics of 162 type III HLP patients and
68 normocholesterolemic E2/2 subjects were compared.
The mean age of the type III HLP patients was significantly
lower and their body mass index (BMI) was higher compared
with corresponding values in the normocholesterolemic E2/2
subjects (Table 1). Coronary artery disease and peripheral
vascular disease were more frequently present in type III HLP
patients, but there were no differences found in the occur-
rence of diabetes mellitus or hypertension or in the number of
smokers and alcohol consumers between the groups. The use
of antihypertensive drugs was significantly higher among
type III HLP patients.
Total cholesterol, triglyceride, VLDL cholesterol (VLDL-
C), and VLDL triglyceride (VLDL-TG) levels and the
VLDL-C/VLDL-TG ratio were increased in type III HLP
patients, whereas HDL cholesterol (HDL-C) was decreased
(Table 2). It has been demonstrated that type III HLP patients
have low LDL cholesterol (LDL-C) levels and increased IDL
cholesterol (IDL-C) levels.2,4,11–13 Thus, the significantly
increased levels of LDL-CIDL-C in type III HLP patients
(Table 2) can be attributed to the high IDL levels present in
these patients. Furthermore, compared with normocholester-
olemic E2/2 subjects, type III HLP patients had significantly
higher fasting insulin levels. In fact, hyperinsulinemia was
observed in 51 (63%) of 81 type III HLP patients, whereas 7
(26%) of 27 normocholesterolemic E2/2 subjects were hy-
perinsulinemic (P0.001).
TABLE 1. Clinical Characteristics of Normocholesterolemic
E2/2 Subjects and Type III HLP Patients
Parameter
Normocholesterolemic
E2/2 Type III HLP
n (%) N n (%) N
Male 39 (57) 68 104 (64) 162
Female 29 (43) 68 58 (36) 162
Age (range), y 6017 (25–88) 68 5112 (22–80)† 162
BMI, kg/m2 25.64.0 63 26.93.8† 162
Xanthomas* ND    67 (54) 123
CAD 6 (10) 58 58 (36)‡ 162
PVD 1 (2) 58 31 (19)‡ 162
CVD 1 (2) 58 11 (7) 162
Hypertension 14 (22) 65 47 (29) 162
Antihypertensive drugs 3 (5) 62 26 (20)‡ 132
Diabetes mellitus 5 (8) 62 16 (10) 162
Smokers 23 (39) 59 64 (40) 161
Alcohol consumers 34 (72) 47 90 (71) 126
n indicates subgroup of patients with given parameter; N, total number of
subjects with available data about the respective parameter; CAD, coronary
artery disease; PVD, peripheral vascular disease; CVD, cerebrovascular dis-
ease; and ND, not determined. Age and BMI are presented as meanSD.
*Including xanthochromia striata palmaris.
†P0.05 vs normocholesterolemic E2/2 subjects (by unpaired Student t
test); ‡P0.05 vs normocholesterolemic E2/2 subjects (by 2 test).
TABLE 2. Biochemical Characteristics of
Normocholesterolemic E2/2 Subjects and Type III HLP Patients
Parameter
Normocholesterol-
emic E2/2 Type III HLP
MeanSD n MeanSD n
TC, mmol/L 5.590.92 68 10.903.43* 162
TG, mmol/L 2.110.88 63 6.574.72† 162
HDL-C, mmol/L 1.360.34 61 1.030.28† 161
VLDL-C, mmol/L 1.470.42 12 6.193.82† 134
LDL-CIDL-C, mmol/L 2.280.83 12 3.581.12† 134
VLDL-TG, mmol/L 1.660.63 12 5.224.53† 125
VLDL-C/VLDL-TG 0.930.21 12 1.300.41† 125
Glucose, mmol/L 5.20.8 28 5.41.2 122
Insulin, pmol/L 6841 27 154133† 81
n indicates total number of subjects with available data about the respective
parameter; TC, total cholesterol; and TG, total triglycerides. TC, TG, VLDL-C,
VLDL-TG, and insulin levels were logarithmically transformed before statistical
analysis.
*Selection criterion.
†P0.05 vs normocholesterolemic E2/2 subjects (by unpaired Student t
test).
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Multiple Linear Regression
Multiple linear regression analysis was used to determine the
effect of age, sex, BMI, hyperinsulinemia, and alcohol
consumption on the total cholesterol, total triglyceride,
VLDL-C, and VLDL-TG levels of the E2/2 population
(normocholesterolemic E2/2 subjects plus type III HLP pa-
tients). Inclusion of all factors in the model explained 30%
of the variability in the expression of type III HLP (Table 3).
Plasma insulin levels had a strong independent effect on total
cholesterol, total triglyceride, VLDL-C, and VLDL-TG lev-
els. Panel A of the Figure shows that the strongest relation-
ship was observed between plasma insulin and total triglyc-
eride levels (Spearman correlation coefficient 0.56,
P0.001). This relationship remained significant after exclu-
sion of 6 apoE2 homozygotes with insulin levels 400
pmol/L (Spearman correlation coefficient 0.50, P0.001).
Furthermore, a significant linear correlation between plasma
insulin and BMI was found (Spearman correlation coefficient
0.25, P0.01; Figure, panel B).
Differences Between Males and Females in the
Onset of Expression of Type III HLP
Type III HLP was more prevalent in men than in women
(Table 1). In men, type III HLP is usually expressed
between 30 and 40 years of age, whereas in women type III
HLP is expressed after menopause.2,3 In accordance, the
prevalence of postmenopausal women was increased in
type III HLP patients compared with normocholesterol-
emic E2/2 subjects (91% versus 69%, respectively;
P0.05; results not shown).
To investigate the effect of sex on the age of onset of
type III HLP, plasma lipid levels were compared between
males and females subdivided in 2 age classes. Table 4
shows that women aged 50 years had significantly lower
levels of total cholesterol and triglycerides than did the
men, whereas HDL-C levels were increased. Compared
with males, females aged 50 years had significantly
increased levels of total cholesterol and similar levels of
total triglycerides and HDL-C. These data indicate that in
E2/2 subjects there is indeed a significant influence of sex
on the age of manifestation of type III HLP. Furthermore,
total cholesterol and triglyceride levels decreased in males
as age increased. In contrast, females aged 50 years had
significantly higher levels of total cholesterol and triglyc-
erides than did their counterparts aged 50 years, indicat-
ing that in females the expression of type III HLP increases
with age, which is most likely due to the loss of estrogen
production.
Discussion
The present study has demonstrated that the prevalence of
type III HLP among middle-aged Dutch apoE2 homozygotes
is 18%. Furthermore, we found that hyperinsulinemia is an
important contributor to the expression of type III HLP,
whereas age has an effect only in women with type III HLP.
TABLE 3. Multiple Linear Regression Analysis for
Logarithmically Transformed Plasma Lipid and Lipoprotein
Levels in E2/2 Subjects
Dependent
Variable
Independent
Variable Partial r Multiple r P * r2
Ln(TC) Ln(insulin) 0.46 0.001
BMI 0.02 0.85
Age 0.01 0.90
Sex† 0.13 0.18
Alcohol† 0.07 0.48
Full model 0.51 0.001 0.26
Ln(TG) Ln(insulin) 0.56 0.001
BMI 0.02 0.83
Age 0.12 0.24
Sex† 0.09 0.39
Alcohol† 0.05 0.64
Full model 0.58 0.001 0.34
Ln(VLDL-C) Ln(insulin) 0.47 0.001
BMI 0.08 0.50
Age 0.02 0.87
Sex† 0.05 0.64
Alcohol† 0.07 0.56
Full model 0.49 0.001 0.24
Ln(VLDL-TG) Ln(insulin) 0.51 0.001
BMI 0.08 0.47
Age 0.15 0.20
Sex† 0.01 0.96
Alcohol† 0.05 0.69
Full model 0.52 0.001 0.27
Partial r indicates partial correlation coefficient; multiple r, multiple corre-
lation coefficient; and r2, determination coefficient. Normocholesterolemic E2/2
subjects and type III HLP patients were included in the statistical analyses.
*Probability for t statistics (partial correlation) or F statistics.
†For sex and alcohol, a numerical code was entered in this analysis.
Scatterplots showing the associations between total triglycer-
ides and plasma insulin (A) and BMI and plasma insulin (B) in
the E2/2 population (normocholesterolemic E2/2 subjects plus
type III HLP patients, n108). The associations are expressed
as Spearman correlation coefficients.
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The prevalence of type III HLP among apoE2 homozy-
gotes has been estimated to be 5%.11,13,21 The higher
prevalence of type III HLP among apoE2 homozygotes in the
present study could be the result of an increased frequency of
apoE2 homozygosity in the Dutch population. However, the
gene frequency in the present study (0.6%) is very similar to
that in other white populations (see review2). Alternatively,
the prevalence of overt type III HLP might be higher in the
Netherlands than in other white populations. Indeed, the
results of the Dutch population sample revealed a prevalence
of 1:900 (10 of 8888), which is comparable to the highest
prevalence documented in the literature.13 There are several
possible explanations for this finding. First, the high age of
the participants of the Rotterdam study might contribute to
the higher prevalence. However, when only the data from the
population study among 35-year-old men are used, the
prevalence of type III HLP is estimated to be 1:700 (3 of
2018). Second, we have estimated the prevalence in a
population-based study containing middle-aged Dutch indi-
viduals, whereas the estimations reported by most other
investigators have been determined in kindreds of type III
HLP patients.11,21 Finally, most estimates have been reported
in the 1970s and 1980s (see review13). Improved methodol-
ogy for the diagnosis of type III HLP since then could have
resulted in an increased frequency. More recently, a study by
Feussner et al22 has shown that the prevalence of type III HLP
among apoE2 homozygous relatives of German type III HLP
patients is 30%, which is even higher than the prevalence
estimated in the present population-based study.
It has been suggested that the expression of type III HLP is
influenced by factors that either stimulate production or
impair the clearance or lipolysis of lipoproteins.2 To investi-
gate these additional factors, we have compared a large group
of type III HLP patients and normocholesterolemic E2/2
subjects. The increased levels of plasma insulin in type III
HLP patients together with the results of the multiple linear
regression analysis clearly demonstrate that hyperinsulinemia
is an important additional factor in the expression of type III
HLP. This is in line with our previous findings in a smaller
group of apoE2 homozygotes.20 Recently, Brümmer et al23
have compared 8 type III HLP patients and 3 normolipidemic
E2/2 subjects. Their study demonstrated increased postpran-
dial insulin levels but normal fasting insulin levels in type III
HLP patients, which were most likely due to the small sample
size. Hyperinsulinemia is known to stimulate VLDL produc-
tion through an increased FFA flux into the liver.18,19 Hepatic
VLDL overproduction in combination with a defective LDLR
binding could lead to a severe accumulation of lipoproteins in
the circulation and overt HLP in apoE2 homozygotes. On the
other hand, hyperinsulinemia could affect lipoprotein lipase–
mediated lipolysis, inasmuch as lipoprotein lipase may be
downregulated by insulin.24
It is commonly assumed that obesity has an impact on
the expression of type III HLP,2 because obesity is known
to stimulate the production and secretion of VLDL.25,26
Although we found a significantly increased BMI in type
III HLP patients compared with normocholesterolemic
E2/2 subjects, BMI had no significant independent effect
on the expression of type III HLP in apoE2 homozygotes.
However, in our apoE2 homozygous population, a signif-
icant relationship was present between plasma insulin
levels and BMI. Because of this correlation, part of the
effect of hyperinsulinemia on the expression of type III
HLP could be derived from the effect of BMI. Neverthe-
less, the use of BMI as a measure for obesity has some
limitations: (1) subjects with a low BMI could have the
same amount of fat as those with a high BMI, and (2) at
different ages, subjects with the same BMI could have
different amounts and distribution of body fat. The waist-
to-hip ratio (WHR) might be a better measure for obesity
and body fat distribution than BMI,27 because it has been
found that women with a high WHR (ie, abdominal
obesity) are more insulin resistant than are women with a
low WHR and the same BMI.28 Unfortunately, we were
unable to collect data about the WHR in our study population.
Therefore, we can only speculate about the importance of a
high WHR for the expression of type III HLP.
Although in apoE2 homozygotes an effect of diabetes
mellitus on the expression of type III HLP has been suggest-
ed,2,3 we found no differences in the frequency of diabetes
mellitus between type III HLP patients and normocholester-
olemic E2/2 subjects. The prevalence of diabetes mellitus
observed in both groups is similar to the prevalence observed
in the Dutch population (8.3%),29 indicating that diabetes
mellitus is no major determinant of type III HLP. In addition,
alcohol consumption had no significant effect on the expres-
sion of type III HLP. This observation is in agreement with
recent data from our group demonstrating that in type III HLP
patients normal alcohol consumption has no effect on plasma
lipid levels.30
TABLE 4. Differences Between Male and Female E2/2 Subjects in Plasma Lipid Levels After
Subdivision Into 2 Age Classes
Age 50 y Age 50 y
Males Females Males Females
MeanSD n MeanSD n MeanSD n MeanSD n
TC, mmol/L 10.084.08 81 6.293.22* 11 8.192.99* 62 9.893.78†‡ 76
TG, mmol/L 6.334.98 81 2.882.36* 11 4.553.14* 60 5.214.92‡ 73
HDL-C, mmol/L 1.010.33 78 1.520.43* 9 1.100.27 60 1.200.32‡ 75
n indicates total number of subjects with available data about the respective parameter. Normocholesterolemic
E2/2 subjects and type III HLP patients were included in the statistical analyses. TC and TG levels were logarithmically
transformed before statistical analysis.
*P0.05 vs males aged 50 y; †P0.05 vs males aged 50 y; and ‡P0.05 vs females aged 50 y.
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A factor that could have a profound effect on lipoprotein
clearance is the number of LDLRs on the liver cell. Although
it has been reported that LDLR number decreases with age,31
our data demonstrate that age is no important independent
contributor to the expression of type III HLP. However, the
observation that women develop type III HLP mostly during
menopause3 and our findings that plasma cholesterol and
triglyceride levels were increased in female apoE2 homozy-
gotes aged 50 years of age strongly suggest that in women
type III HLP expression is influenced by estrogen balance
rather than age itself. In contrast, a small decrease in plasma
lipids was observed in men aged 50 years. The latter is in
agreement with the results from a study among male apoE2
homozygotes aged 35 years showing that their lipid levels
remained essentially unchanged after 10 years of follow-up.20
However, it is important to note that the apparent leveling off
in expression of type III HLP in men with advancing age
might be confounded by ascertainment bias in the overrepre-
sentation of younger men with more severe forms of the
disorder in vascular or dermatology clinics and the later
appearance of men with probably milder forms of type III
HLP who have escaped complications until an older age.
Furthermore, in men, the manifestation of type III HLP might
also increase with age, but this could remain undetected
because of the earlier cardiovascular deaths of those affected
with type III HLP.
The present data show that 25% of the variability in
expression of type III HLP in apoE2 homozygotes can be
explained by hyperinsulinemia and that an additional 3% can
be explained by sex, age, BMI, and alcohol consumption.
Other additional risk factors remain to be determined. Family
studies have provided evidence that the simultaneous occur-
rence of apoE2 homozygosity and genes causing familial
combined hyperlipidemia or hypertriglyceridemia can result
in the clinical expression of type III HLP.11,22,32 These
observations in combination with our data suggest that
possible candidates could be mutations in genes regulating
VLDL metabolism and in genes associated with insulin
resistance. The insulin resistance syndrome is characterized
by dyslipidemia, hypofibrinolysis, hypertension, and insulin
resistance18,33,34. Although euglycemic clamp studies have
not been performed in type III HLP patients to determine their
insulin sensitivity, the increased BMI and the high prevalence
of hypertension and hyperinsulinemia found in the present
study suggest that the insulin resistance syndrome plays a
pivotal role in the etiology of type III HLP.
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